The Medicines Company Stock price

Equities

MDCO

US5846881051

Pharmaceuticals

Delayed Nasdaq 5-day change 1st Jan Change
- USD -.--% Intraday chart for The Medicines Company +0.14% -0.05%
Sales 2017 44.79M Sales 2018 6.14M Capitalization 1.41B
Net income 2017 -708M Net income 2018 -123M EV / Sales 2017 55.1 x
Net Debt 2017 498M Net Debt 2018 552M EV / Sales 2018 319 x
P/E ratio 2017
-2.79 x
P/E ratio 2018
-11.4 x
Employees -
Yield 2017 *
-
Yield 2018
-
Free-Float 92.97%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Investor Relations Contact - -
General Counsel 47 -
Members of the board TitleAgeSince
Director/Board Member 81 -
More insiders
The Medicines Company is a global biopharmaceutical company. The Company is focused on the development of inclisiran, a twice-yearly therapy that allows administration during patients routine visits to their healthcare professionals and potentially contributes to improved patient adherence and sustained lower LDL-C levels. The Company is a subsidiary of Novartis AG.
More about the company
  1. Stock
  2. Equities
  3. Stock The Medicines Company - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer